While Novavax’s adjuvanted Nuvaxovid (NVX-CoV2373) vaccine is not currently approved or licensed by the US Food and Drug Administration (FDA), it has been authorised by the agency under an ...

Sanofi – which has taken a sub-5% equity stake in Novavax for $70 million – said the alliance will expand access to the biotech’s protein-based adjuvanted COVID vaccine Nuvaxovid/Covovax ...

In the first of a double dose of wins for US biotech Novavax, the company has been granted full marketing authorisation (MA) by the European Commission in the EU for Nuvaxovid (NVX-CoV2373 ...

Nuvaxovid, a two-shot treatment to prevent ... The protein is combined with Novavax's Matrix-M adjuvant, which is important in enhancing the immune response elicited by the protein antigen.

With Sanofi (SNY) expected to join the company’s commercialization efforts in 2025, many issues Novavax (NVAX) encountered with the rollout of its COVID-19 shot, Nuvaxovid, in the 2023–24 ...

I have been warning about Novavax's risks since 2016, highlighting its ongoing struggles with the FDA. Novavax's Q3 2024 earnings call and 10-Q reveal a collaboration negotiated from a position of ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.